BRAVE-3: Bronchial Sample Collection for a Novel Genomic Test - 3
Phase: Specimen Collection
Status: Not Recruiting
The purpose of this study is to optimize a genetic test that will provide a range of diagnostic and prognostic information about interstitial lung disease (ILD). ILDs are a diverse group of pulmonary disorders in which there is a disruption of the lung parenchyma (portion of lung involved in gas transfer) resulting in pulmonary fibrosis (thickening of lung tissue) and progressive dyspnea (difficult or labored breathing) related to restrictive lung disease. Idiopathic Pulmonary Fibrosis (IPF) is a serious form of a group of lung diseases known as interstitial lung diseases. IPF is a disease in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. It is very important to diagnose the lung disease accurately, as this helps physicians make the best treatment decisions. Subjects undergoing bronchoscopy and cryobiopsy as part of their standard clinical evaluation for ILD will be enrolled. Bronchoscopy is a procedure that involves inserting a tube into the lung through the throat and a cryobiopsy is a technique which allows physicians to obtain biopsy samples using a cryoprobe (a special probe cold enough to freeze only the lung tissue it is touching). Additional samples will be collected for the purpose of the study and the specimen size is small compared to the one obtained using standard surgical lung biopsy. The samples will be sent to Veracyte, Inc. to help them develop the diagnostic test.